Results from the analysis of the physician preferences for G-CSF as primary and secondary prophylaxes
| G-CSF attribute | As primary prophylaxis | As secondary prophylaxis | ||
| Coefficient (error type) | P value | Coefficient (error type) | P value | |
| Efficacy | ||||
| Risk of febrile neutropenia with prophylaxis | 0.039 (0.016) | 0.015 | 0.094 (0.017) | <0.001 |
| G-CSF characteristic | ||||
| Biosimilar | 0.145 (0.018) | <0.001 | 0.110 (0.018) | <0.001 |
| G-CSF administration and cost | ||||
| Cost per injection, including cost of nurse (euros) | 0.114 (0.010) | <0.001 | 0.106 (0.011) | <0.001 |
| Number of injections per chemotherapy cycle | 0.212 (0.010) | <0.001 | 0.137 (0.011) | <0.001 |
| Tolerance | ||||
| Pain at the injection site | 0.077 (0.016) | <0.001 | 0.046 (0.017) | 0.005 |
| Bone pain present | −0.040 (0.016) | 0.012 | −0.072 (0.017) | <0.001 |
| Fever/influenza syndrome present | −0.037 (0.016) | 0.023 | −0.051 (0.017) | 0.002 |
G-CSF, granulocyte colony-stimulating factors.